title: Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder.
abstract: BACKGROUND
  This study aimed to examine the impact of quetiapine on the symptom and distress domains measured by the Symptom Checklist-90-Revised (SCL-90-R) in patients with borderline personality disorder (BPD).
  
  
  METHODS
  Ninety-five participants meeting DSM-IV diagnostic criteria for BPD were randomly assigned to low-dosage (quetiapine, 150 mg/d; n = 33), moderate-dosage (quetiapine, 300 mg/d; n = 33), or placebo (n = 29). SCL-90-R was administered weekly over the course of an 8-week double-blind treatment phase. We used a mixed-effects model to analyze subscale scores of the SCL-90-R.
  
  
  RESULTS
  Results showed that both dosages of quetiapine were effective in reducing levels of overall psychological distress, interpersonal sensitivity, depression, and hostility compared with those who received placebo.
  
  
  CONCLUSIONS
  SCL-90-R can be a useful tool that would allow clinicians to collect information in addition to the DSM symptoms to better understand the diagnostic heterogeneity found in patients diagnosed with BPD.
authors: Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA. E-mail: leexx310@umn.edu.
authors: Susanne S
authors: SS
authors: Lee
authors: Jeff
authors: J
authors: Allen
authors: Donald W
authors: DW
authors: Black
authors: Mary C
authors: MC
authors: Zanarini
authors: S Charles
authors: SC
authors: Schulz
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D017063:Outcome Assessment, Health Care / Q000379:methods*; D000069348:Quetiapine Fumarate / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D000069348:Quetiapine Fumarate